Intermune (ITMN) 10-Q 7 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 31, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'ITMN	'
Entity Registrant Name	'INTERMUNE INC	'
Entity Central Index Key	'0001087432	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	107,969,163

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$208,562	$191,433
Available-for-sale securities	351,623	195,574
Accounts receivable, net	31,019	21,436
Inventories	10,992	11,125
Prepaid expenses and other current assets	11,232	9,600
Total current assets	613,428	429,168
Property and equipment, net	4,909	4,706
Acquired product rights, net	16,750	17,250
Other assets (includes restricted cash of $3,759 at June 30, 2014 and $4,531 at December 31, 2013)	8,933	11,509
Total assets	644,020	462,633
Current liabilities:	'	'
Accounts payable	14,613	16,778
Accrued compensation and benefits	16,166	17,148
Convertible notes - current	18,360	'
Accrued expenses and other current liabilities	38,574	29,122
Total current liabilities	87,713	63,048
Convertible notes - noncurrent	216,118	265,102
Other long-term liabilities	143	200
Commitments and contingencies (Note 11)	'	'
Stockholders’ equity:	'	'
Preferred stock, $0.001 par value; 5,000 shares authorized, no shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively	'	'
Common stock, $0.001 par value; 175,000 shares authorized; 102,918 and 89,608 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively	103	90
Additional paid-in capital	1,781,544	1,450,937
Accumulated other comprehensive income	757	774
Accumulated deficit	-1,442,358	-1,317,518
Total stockholders' equity	340,046	134,283
Total liabilities and stockholders’ equity	$644,020	$462,633

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Other assets, restricted cash	$3,759	$4,531
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	175,000,000	175,000,000
Common stock, shares issued	102,918,000	89,608,000
Common stock, shares outstanding	102,918,000	89,608,000

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenue, net	'	'	'	'
Esbriet product sales	$35,739	$14,400	$66,013	$24,930
Cost and expenses:	'	'	'	'
Cost of goods sold	5,770	1,943	9,135	4,319
Research and development	39,746	27,531	71,797	53,407
Selling, general and administrative	52,632	37,273	96,959	67,249
Total costs and expenses	98,148	66,747	177,891	124,975
Loss from operations	-62,409	-52,347	-111,878	-100,045
Other income (expense):	'	'	'	'
Interest income	266	115	369	252
Interest expense	-3,902	-3,634	-7,762	-7,117
Change in value of embedded conversion derivative	'	-6,336	'	2,422
Loss on extinguishment of notes	-4,934	'	-4,934	-7,900
Other	-382	-574	-684	-94
Loss from continuing operations before income taxes	-71,361	-62,776	-124,889	-112,482
Income tax provision	152	481	642	880
Loss from continuing operations, net of income taxes	-71,513	-63,257	-125,531	-113,362
Income from discontinued operations, net of income taxes	320	387	691	617
Net loss	($71,193)	($62,870)	($124,840)	($112,745)
Basic and diluted net income (loss) per common share:	'	'	'	'
Continuing operations	($0.72)	($0.78)	($1.32)	($1.43)
Discontinued operations	'	$0.01	'	$0.01
Net loss per share	($0.72)	($0.77)	($1.32)	($1.42)
Shares used in computing basic and diluted net income (loss) per common share	99,209	81,210	94,898	79,321

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net loss	($71,193)	($62,870)	($124,840)	($112,745)
Other comprehensive loss:	'	'	'	'
Foreign currency translation adjustment	144	-109	88	-664
Unrealized gains (losses) on available-for-sale securities:	'	'	'	'
Unrealized losses during period	-96	-90	-104	-135
Less: Reclassification adjustments for gains (losses) transferred to net loss	-1	2	-1	2
Total other comprehensive income (loss)	47	-197	-17	-797
Comprehensive loss	($71,146)	($63,067)	($124,857)	($113,542)

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Cash flows used in operating activities:	'	'
Net loss	($124,840)	($112,745)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Stock-based compensation expense	9,488	5,493
Amortization of note discount and note issuance costs	3,850	3,187
Change in fair value of embedded conversion derivative	'	-2,422
Depreciation and amortization expense	1,543	1,325
Loss on extinguishment of notes	4,934	7,900
Net realized (gains) losses on sales of available-for-sale securities	1	-2
Other	42	-68
Changes in operating assets and liabilities:	'	'
Accounts receivable, net	-9,583	-4,893
Inventories	133	191
Prepaid expenses	-1,632	-1,317
Other assets	796	-342
Accounts payable and accrued compensation	-3,147	-9,206
Other accrued liabilities	9,452	1,187
Net cash used in operating activities	-108,963	-111,712
Cash flows from investing activities:	'	'
Purchases of property and equipment	-1,246	-542
Purchases of available-for-sale securities	-259,329	-148,290
Maturities of available-for-sale securities	103,174	88,177
Sales of available-for-sale securities	'	21,014
Net cash used in investing activities	-157,401	-39,641
Cash flows from financing activities:	'	'
Proceeds from issuance of common stock in a public offering, net of issuance costs	267,953	145,734
Proceeds from convertible notes, net of issuance costs	'	116,800
Debt extinguishment costs	-558	-72,183
Proceeds from issuance of common stock under employee stock benefit plans	16,109	1,361
Net cash provided by financing activities	283,504	191,712
Effect of exchange rate changes on cash and cash equivalents	-11	-582
Net increase in cash and cash equivalents	17,129	39,777
Cash and cash equivalents at beginning of period	191,433	117,748
Cash and cash equivalents at end of period	208,562	157,525
Supplemental disclosure of cash flow information:	'	'
Interest paid in cash	3,933	4,906
Non-cash financing activities:	'	'
Reclassification of derivative liability to stockholders' equity	'	34,465
Reclassification of debt exchange to stockholders' equity	$37,069	'

Organization

Organization	6 Months Ended
	Jun. 30, 2014
Organization	'
	1.   ORGANIZATION
	Overview
	InterMune, Inc. (“InterMune,” “we,” and the “Company”) is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, we are focused on therapies for the treatment of idiopathic pulmonary fibrosis, or IPF, a progressive and fatal lung disease. We have a product in pulmonology, pirfenidone, which is an orally active, small-molecule compound. Pirfenidone was granted marketing authorization effective February 2011 in all 28 member countries of the European Union, or the EU, for the treatment of adults with mild to moderate IPF. In September 2011, we launched commercial sales of pirfenidone in Germany under the trade name Esbriet®, and Esbriet is now also commercially available in various European countries, including key markets such as France, Italy and the UK. In addition, we launched in Canada in January 2013.
	We are also pursuing the registration of pirfenidone to treat IPF in the United States. After reviewing various regulatory and clinical development options and following our discussions with the United States Food and Drug Administration, or FDA, we commenced an additional pivotal Phase 3 clinical study of pirfenidone in IPF in July 2011, known as the ASCEND trial. In February 2014, we announced top-line results of ASCEND and in May 2014 we resubmitted our Class 2 New Drug Application, or NDA, to the FDA to support regulatory registration in the United States. The FDA confirmed that the resubmitted NDA had been filed and that it has assigned a Prescription Drug User Fee Act goal date of November 23, 2014. In addition, on July 17, 2014, the FDA assigned Breakthrough Therapy Designation status for pirfenidone.
	In March 2014, we completed a registered underwritten public offering of 8,625,000 shares of our common stock. The resulting aggregate net proceeds from the common stock offering were approximately $268.0 million, after deducting underwriting discounts and expenses.
	In June 2014, we completed the exchange of $43.1 million in aggregate principal amount of our 2.50% convertible senior notes due 2017 Notes (the “2017 Notes”) beneficially owned by certain existing holders of our 2017 Notes for an aggregate of 3,378,457 shares of our common stock (the “Exchange Shares”), valued at $47.22 per share, plus accrued but unpaid interest. The notes were exchanged at a rate of 78.3884 shares per $1,000 note, which represents an exchange price of approximately $12.77 per share and an approximate $0.10 discount from the original conversion price of the 2017 Notes of $12.87 per share. See Note 9 to these financial statements for details of this exchange.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Summary of Significant Accounting Policies	'
	2.   SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Our significant accounting policies and recent accounting pronouncements were described in Note 2 to our Consolidated Financial Statements included in our 2013 Annual Report on Form 10-K for the fiscal year ended December 31, 2013. There have been no significant changes in our accounting policies since December 31, 2013.
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. The financial statements include all adjustments (consisting only of normal recurring adjustments) that we believe are necessary for a fair presentation of the periods presented. The condensed consolidated balance sheet at December 31, 2013 was derived from the audited consolidated financial statements, but does not include all disclosures required by GAAP. These interim financial results are not necessarily indicative of results to be expected for the full fiscal year or any other future period and should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2013, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission, or SEC.
	Revenue Recognition
	Revenue is generated from product sales and recorded net of mandatory government rebates. We only ship product upon receipt of valid orders from customers, such as pharmacies and hospitals, which are in turn a result of actual patient prescriptions. Delivery is considered to have occurred when title passes to a credit-worthy customer. We include shipping and handling costs in cost of goods sold. Pursuant to terms and conditions of sale, our customers have no general right of product return but we permit returns if the product is damaged or defective when received by the customer. Such restriction on product returns is common practice in the markets in which we sell, and as a result, we have had no significant expenses related to product returns, damaged or expired goods.
	To date, all significant amounts recorded as estimates of items that reduce gross revenue related solely to mandatory government rebates, many of which were negotiated on a confidential basis with the respective government reimbursement agencies. Our estimation of these rebates requires only the application of pre-specified rates, determined as part of pre-launch pricing negotiations with the relevant government reimbursement agencies, to sales of our product as applicable. We recognize these mandatory government rebates as reductions of product sales and the recording of these rebates is substantially mechanical in nature and does not involve the application of significant judgment. Fluctuations in the amounts recorded for these rebates relate solely to increased sales or the eventual payment of amounts due to the various government agencies. To date, we have had no significant charges or credits related to prior period estimates.
	Derivative Financial Instruments
	On January 22, 2013, we issued $120.8 million aggregate principal amount of 2.50% convertible senior notes due 2017 (the “2017 Notes”). As a result of our issuance of the 2017 Notes, our total potential outstanding common stock exceeded our authorized shares by approximately 4.3 million shares as of that date and we were therefore required to value the embedded conversion derivative and recognize it at fair value as a long-term liability.
	On May 30, 2013, we obtained stockholder approval to an amendment to our certificate of incorporation to increase the number of our authorized shares of common stock from 100,000,000 to 175,000,000. As a result of the increase in authorized number of shares, we can now settle the 2017 Notes in cash, stock, or a combination thereof, solely at our election, the derivative associated with the embedded conversion derivative was marked to fair value at May 30, 2013 and the long-term liability was reclassified to stockholders’ equity.
	See Note 10 for further details of our embedded conversion derivative.
	Net Income (Loss) Per Share
	Basic net loss per share is calculated based on the weighted-average number of shares of our common stock outstanding during the period, as adjusted. Diluted net loss per share is calculated based on the weighted average number of shares of our common and other dilutive securities outstanding during the period. The potential dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and shares subject to repurchase are determined under the treasury stock method. The potential dilutive shares of our common stock issuable on conversion of our convertible notes are determined using the “if-converted” method. Anti-dilutive securities, which consist of stock options, restricted stock awards and units, and shares that could be issued upon conversion of our convertible notes, are not included in the diluted net loss per share calculation.
	For the calculation of net loss per share, anti-dilutive securities excluded were as follows:
		As of
		June 30,
		2014			2013
		(in thousands)
	Common stock options and restricted awards and units		6,342			6,095
	Shares issuable upon conversion of convertible notes		11,888			15,237
	The following table is a reconciliation of the denominator used in the calculation of basic and diluted net loss per share attributable to our common stockholders:
		Three Months						Six Months
		Ended June 30,						Ended June 30,
		2014			2013			2014			2013
		(in thousands)
	Denominator:
	Weighted-average shares of common stock outstanding		99,631			81,823			95,360			79,924
	Less: Weighted-average shares subject to repurchase		(422	)		(613	)		(462	)		(603	)
	Weighted-average shares used in computing net income (loss) per common share – basic and diluted		99,209			81,210			94,898			79,321
	Stock-Based Compensation
	The following table reflects stock-based compensation expense recognized for the three and six month periods ended June 30, 2014 and 2013:
		Three Months						Six Months
		Ended June 30,						Ended June 30,
		2014			2013			2014			2013
		(in thousands)
	Cost of goods sold	$	37		$	15		$	64		$	43
	Research and development		1,411			667			2,559			1,664
	Selling, general and administrative		3,757			2,023			6,865			3,786
	Total stock-based compensation expense	$	5,205		$	2,705		$	9,488		$	5,493
	Under the fair value recognition provisions of Accounting Standards Codification (ASC) 718-10, Stock Compensation, stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the vesting period for that portion of the award that is ultimately expected to vest. In order to estimate the value of share-based awards, we use the Black-Scholes model, which requires the use of certain subjective assumptions. The most significant assumptions are our estimates of the expected volatility, the expected term of the award and the estimated forfeiture rate.
	Segment Reporting
	We have determined, in accordance with ASC 280, Segment Reporting, that our business operates in one operating segment: the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.
	Recent Accounting Pronouncements
	In April 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-08, Presentation of Financial Statements and Property, Plant and Equipment. This ASU is an amendment to the discontinued operations accounting guidance. The amendment raises the threshold for a disposal to qualify as a discontinued operation and requires new disclosures for both discontinued operations and disposals of individually significant components that don’t qualify as discontinued operations. We adopted ASU No. 2014-08 for the period ended June 30, 2014. The adoption of this new guidance did not have an effect on our condensed consolidated balance sheets, statement of operations or cash flows.

Discontinued_Operations

Discontinued Operations	6 Months Ended
	Jun. 30, 2014
Discontinued Operations	'
	3.   DISCONTINUED OPERATIONS
	On June 19, 2012, we completed the divestiture of our worldwide development and commercialization rights to the pharmaceutical product containing Interferon Gamma-1b sold by us under the trade name Actimmune for $55.0 million in cash, plus certain conditional royalty payments for a period of two years following the closing (the transaction is referred to herein as the “Asset Sale”). The Asset Sale was consummated pursuant to the terms of the Asset Purchase Agreement, dated as of May 17, 2012, by and among InterMune and Vidara Therapeutics International Limited, an Irish company, Vidara Therapeutics Holdings LLC, a Delaware limited liability company and Vidara Therapeutics Research Limited, an Irish company, as amended on June 18, 2012. The operating results of our Actimmune activities have been reclassified as discontinued operations for all periods presented. As a consequence of the divestiture, we were required to apply intraperiod tax allocation rules for the purposes of calculating our provision (benefit) for income taxes.
	Results of Discontinued Operations
	Summary operating results for the discontinued operations are as follows:
		Three Months					Six Months
		Ended June 30,					Ended June 30,
		2014		2013			2014		2013
		(in thousands)
	Actimmune revenue, net	$	500	$	500		$	1,077	$	1,000
	Costs and expenses:
	General and administrative		15		(81	)		30		65
	Total costs and expenses		15		(81	)		30		65
	Income from discontinued operations		485		581			1,047		935
	Income and gains related to discontinued operations, before tax		485		581			1,047		935
	Income tax expense		165		194			356		318
	Income from discontinued operations, net of taxes	$	320	$	387		$	691	$	617

Derivative_Instruments

Derivative Instruments	6 Months Ended
	Jun. 30, 2014
Derivative Instruments	'
	4.   DERIVATIVE INSTRUMENTS
	We conduct business throughout Europe and Canada and therefore, we are exposed to adverse movements in foreign currency exchange rates. To limit the exposure related to foreign currency changes, we enter into foreign exchange forward contracts to reduce the short-term effects of foreign currency fluctuations on assets and liabilities such as foreign currency receivables and payables. We do not enter into such contracts for trading or speculative purposes. These derivatives are not designated as hedging instruments. Gains and losses on the contracts are included in “other” as a component of other income (expense) in our condensed consolidated statements of operations and substantially offset foreign exchange gains and losses from the remeasurement of intercompany balances. Our net contract losses were $0.1 million for the three month periods ended June 30, 2014 and 2013, respectively. Our net contract losses for the six month period ended June 30, 2014 were $0.1 million compared to net gains of $0.1 million in the same period in 2013. The notional value of our outstanding currency hedges was 17.7 million Euros and 5.5 million Canadian dollars at June 30, 2014 and 9.5 million Euros at December 31, 2013, and the fair value of these outstanding derivatives at June 30, 2014 was zero and at December 31, 2013 was a loss of $0.2 million.
	Our foreign exchange forward contracts expose us to credit risk to the extent that the counterparties may be unable to meet the terms of the agreement. We do, however, seek to mitigate such risks by limiting counterparties to major financial institutions. In addition, the potential risk of loss with any one counterparty resulting from this type of credit risk is monitored. We are not generally required to pledge collateral under these agreements. We do not expect material losses as a result of defaults by counterparties.
	In addition to our foreign exchange forward contract derivative instruments, we also had an embedded derivative option related to our 2017 Notes. See Note 10 to these financial statements for details of our embedded conversion derivative.

Fair_Value

Fair Value	6 Months Ended
	Jun. 30, 2014
Fair Value	'
	5.   FAIR VALUE
	In accordance with ASC 820-10, Fair Value Measurements and Disclosures, we determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:
	—	Level 1 inputs which include quoted prices in active markets for identical assets or liabilities;
	—	Level 2 inputs which include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. For our available-for-sale securities, we review trading activity and pricing as of the measurement date. For our convertible senior notes we determined the fair value based on quoted market values. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data; and
	—	Level 3 inputs which include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management judgment or estimation.
	The following table represents the fair value hierarchy for our financial assets which require fair value measurement on a recurring basis as of June 30, 2014 and December 31, 2013:
		As of June 30, 2014
		(in thousands)
	Assets	Level 1		Level 2			Level 3		Total
	Money market funds	$	52,364	$	—		$	—	$	52,364
	Obligations of government-sponsored enterprises		—		230,682			—		230,682
	Corporate debt securities		—		120,941			—		120,941
	Commercial paper		—		4,999			—		4,999
	Total	$	52,364	$	356,622		$	—	$	408,986
		As of December 31, 2013
		(in thousands)
	Assets	Level 1		Level 2			Level 3		Total
	Money market funds	$	40,739	$	—		$	—	$	40,739
	Obligations of government-sponsored enterprises		—		145,942			—		145,942
	Corporate debt securities		—		39,134			—		39,134
	Commercial paper		—		26,662			—		26,662
	Total	$	40,739	$	211,738		$	—	$	252,477
	Level 2 Inputs
	We estimate the fair values of our governmental related debts and corporate debt by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data, and other observable inputs. Our foreign currency derivatives contracts have maturities less than three months and all are with counterparties that have a minimum credit rating of A or equivalent by Standard & Poor’s, Moody’s Investors Service, Inc. or Fitch, Inc. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency rates, London Interbank Offered rates (LIBOR) and swap rates. These inputs, where applicable, are at commonly quoted intervals.
	The following table summarizes the carrying and fair value of our Level 2 convertible senior notes as of June 30, 2014 and December 31, 2013:
		As of June 30, 2014					As of December 31, 2013
		(in thousands)
		Carrying value		Fair value			Carrying value		Fair value
	Convertible senior notes due 2015	$	18,360	$	43,026		$	18,360	$	21,028
	Convertible senior notes due 2017		60,868		267,380			91,492		166,563
	Convertible senior notes due 2018		155,250		232,566			155,250		139,930
	Total	$	234,478	$	542,972		$	265,102	$	327,521
	Embedded Conversion Derivative
	The embedded conversion derivative on the 2017 Notes was reclassified to stockholders’ equity on May 30, 2013 in connection with the approval of an amendment to our certificate of incorporation increasing our authorized number of shares of common stock. The embedded conversion derivative was classified as Level 3 because this liability was not actively traded and was valued using a binomial lattice model. Significant inputs to this model were the remaining time to maturity, volatility and risk-free interest rate.
	The following table sets forth the changes in the estimated fair value for our Level 3 classified embedded conversion derivative:
		Three Months					Six Months
		Ended June 30,					Ended June 30,
		2014		2013			2014		2013
		(in thousands)
	Fair value measurement at beginning of period	$	—	$	28,129		$	—	$	—
	Embedded conversion derivative recorded in connection with 2017 Notes		—		—			—		36,887
	Change in fair value measurement included in operating expenses		—		6,336			—		(2,422	)
	Derivative liability reclassified to stockholders’ equity		—		(34,465	)		—		(34,465	)
	Fair value measurement at end of period	$	—	$	—		$	—	$	—

Cash_Equivalents_and_Available

Cash Equivalents and Available-for-Sale Securities	6 Months Ended
	Jun. 30, 2014
Cash Equivalents and Available-for-Sale Securities	'
	6.   CASH EQUIVALENTS AND AVAILABLE-FOR-SALE SECURITIES
	The following table is a summary of available-for-sale debt and equity securities included in cash and cash equivalents or available-for-sale securities:
				Gross		Gross
		Amortized		unrealized		unrealized
		cost		gains		losses			Fair value
	30-Jun-14	(in thousands)
	Money market funds	$	52,364	$	—	$	—		$	52,364
	Obligations of government-sponsored enterprises		230,688		58		(64	)		230,682
	Corporate debt securities		120,980		16		(55	)		120,941
	Commercial paper		4,999		—		—			4,999
	Total	$	409,031	$	74	$	(119	)	$	408,986
		Amortized
		cost		Fair value
		(in thousands)
	Reported as:
	Cash equivalents	$	57,363	$	57,363
	Available-for-sale securities		351,668		351,623
	Total	$	409,031	$	408,986
				Gross		Gross
		Amortized		unrealized		unrealized
		cost		gains		losses			Fair value
	31-Dec-13	(in thousands)
	Money market funds	$	40,739	$	—	$	—		$	40,739
	Obligations of government-sponsored enterprises		145,890		52		—			145,942
	Corporate debt securities		39,123		18		(7	)		39,134
	Commercial paper		26,662		—		—			26,662
	Total	$	252,414	$	70	$	(7	)	$	252,477
		Amortized
		cost		Fair value
		(in thousands)
	Reported as:
	Cash equivalents	$	56,903	$	56,903
	Available-for-sale securities		195,511		195,574
	Total	$	252,414	$	252,477
	Cash and cash equivalents in the tables above exclude cash of $151.2 million as of June 30, 2014 and $134.5 million as of December 31, 2013.
	Realized gains and losses calculated based on the specific identification method were immaterial for the three and six months ended June 30, 2014 and 2013.
	The following is a summary of the amortized cost and estimated fair value of available-for-sale securities by contractual maturity:
		30-Jun-14
		Amortized
		cost		Fair value
		(in thousands)
	Mature in less than one year	$	207,523	$	207,540
	Mature in one to three years		201,508		201,446
	Total	$	409,031	$	408,986

Inventories

Inventories	6 Months Ended
	Jun. 30, 2014
Inventories	'
	7.   INVENTORIES
	Inventories consist of the following:
		June 30,		December 31,
		2014		2013
		(in thousands)
	Raw materials	$	5,653	$	6,962
	Work in process		3,317		1,951
	Finished goods		2,022		2,212
	Inventories	$	10,992	$	11,125

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	6 Months Ended
	Jun. 30, 2014
Accumulated Other Comprehensive Income	'
	8.   ACCUMULATED OTHER COMPREHENSIVE INCOME
	The components of accumulated other comprehensive income, net of taxes, were as follows:
							Accumulated
		Foreign		Unrealized gains			other
		currency		(losses) on			comprehensive
		translation		securities			income
		(in thousands)
	Balance at December 31, 2013	$	711	$	63		$	774
	Changes in components of other comprehensive income (loss)		88		(105	)		(17	)
	Balance at June 30, 2014	$	799	$	(42	)	$	757
	Realized gains and losses were immaterial and were reclassified to other income (expense) on the condensed consolidated statements of operations for the three and six months ended June 30, 2014 and 2013, respectively.

Convertible_Notes

Convertible Notes	6 Months Ended
	Jun. 30, 2014
Convertible Notes	'
	9.   CONVERTIBLE NOTES
	In June 2008, we issued $85.0 million in 5.00% convertible senior notes due 2015 (the “2015 Notes”). The 2015 Notes are senior unsecured obligations of the Company and rank equally in right of payment with all of our existing senior notes, and rank senior in right of payment to all of our existing subordinated notes. Interest accrues from the date of issuance and is payable in arrears on March 1 and September 1 of each year commencing on September 1, 2008. The 2015 Notes will mature on March 1, 2015. Holders of the 2015 Notes may surrender their notes, in integral multiples of $1,000 principal amount, for conversion any time prior to the close of business on the second business day immediately preceding the maturity date. The initial conversion rate for each $1,000 aggregate principal amount of the 2015 Notes is 52.9661 shares of common stock, equivalent to a conversion price of approximately $18.88 per share. Offering expenses and underwriting discounts in the aggregate of approximately $0.6 million related to the sale of the 2015 Notes were recorded in other assets and are being amortized to interest expense using the effective interest method over the term of the 2015 Notes, which is approximately seven years from the date of issuance. At June 30, 2014, $18.4 million of principal remained outstanding under the 2015 Notes which comes due within 12 months of the reporting date and has been reclassified to current liabilities.
	In September 2011, we issued $155.3 million in 2.50% convertible senior notes due 2018 (the “2018 Notes”). The 2018 Notes are general unsecured senior obligations of the Company and rank equal in right of payment with the Company’s other senior unsecured notes and rank senior in right of payment to all of our existing and future subordinated notes. Interest accrues from the date of issuance and is payable in arrears on September 15 and March 15 of each year commencing on March 15, 2012. The 2018 Notes will mature on September 15, 2018. Holders of the 2018 Notes may surrender their notes, in integral multiples of $1,000 principal amount, for conversion any time prior to the close of business on the second business day immediately preceding the maturity date. The initial conversion rate for each $1,000 aggregate principal amount of the 2018 Notes is 31.4465 shares of common stock, equivalent to a conversion price of approximately $31.80 per share. Offering expenses and underwriting discounts in the aggregate of approximately $5.0 million related to the sale of the 2018 Notes were recorded in other assets and are being amortized to interest expense using the effective interest method over the term of the 2018 Notes, which is approximately seven years from the date of issuance. At June 30, 2014, $155.3 million of principal remained outstanding under the 2018 Notes.
	In January 2013, we completed a registered underwritten public offering of 15,525,000 shares of our common stock (“Common Stock Offering”) and a concurrent registered underwritten public offering of $120.8 million aggregate principal amount of 2.50% convertible senior notes due December 15, 2017 (the “2017 Notes” and the “Convertible Note Offering”). The resulting aggregate net proceeds from the Common Stock Offering were approximately $145.7 million, after deducting underwriting discounts and expenses. The resulting aggregate net proceeds from the Convertible Note Offering were approximately $116.8 million, after deducting underwriting discounts and expenses. Interest accrues from the date of issuance and is payable in arrears on June 15 and December 15 of each year commencing on June 15, 2013. The holders of the 2017 Notes may convert their 2017 Notes into shares of our common stock at a conversion rate of 77.7001 shares per $1,000 principal amount of notes, subject to adjustment (representing a conversion price of approximately $12.87 per share). We can settle conversion of the 2017 Notes by delivery of shares, cash or a combination of shares and cash at our election.
	Conversion of the 2017 Notes may occur on any day prior to September 15, 2017, under the following conditions: a) during any fiscal quarter beginning after June 30, 2013, if the last reported sale price of our common stock for at least 20 trading days during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price on each applicable trading day; b) during the five consecutive business day period after any five consecutive trading day period in which the trading price of the 2017 Notes falls below 98% of the product of (i) the last reported sale price of the Company’s common stock and (ii) the applicable conversion rate on each such trading date; c) if we call the 2017 Notes for redemption, at any time prior to the close of business on the second scheduled trading day prior to the redemption date; and d) upon the occurrence of specified corporate events, as defined in the 2017 Notes. From September 15, 2017 until the close of business on the second scheduled trading day immediately preceding the December 15, 2017 maturity date, holders of the 2017 Notes may convert their notes at any time, regardless of the foregoing circumstances.
	On or after June 20, 2015, we may redeem for cash all or part of the 2017 Notes (except for Notes that holders have already required us to repurchase following certain fundamental changes defined within the agreement such as an acquisition or liquidation of the Company) but only if the last reported sale price of our common stock for 20 or more trading days in a period of 30 consecutive trading days ending within 10 trading days of immediately prior to the date we provide the notice of redemption exceeds 130% of the conversion price in effect on each such trading day. The redemption price in this case will equal 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.
	Other than restrictions relating to certain fundamental changes and consolidations, mergers or asset sales and customary anti-dilution adjustments, the 2017 Notes do not contain any financial covenants and do not restrict us from paying dividends or issuing new securities or repurchasing any of our other securities. At June 30, 2014, $77.7 million of principal remained outstanding under the 2017 Notes.
	In January 2013, we used a portion of the net proceeds from the Convertible Note Offering to repurchase approximately $66.6 million of our outstanding 2015 Notes for proceeds of $72.2 million. This repurchase was accounted for as an extinguishment of notes and we recorded a loss on extinguishment of notes of $7.9 million which comprised $5.5 million of premium paid to the holders of the 2015 Notes, $2.2 million related to the excess of the deemed issuance fair value over the issuance price (par) of the 2017 Notes (but only for those holders of the repurchased 2015 Notes who subsequently invested in our 2017 Notes) and $0.2 million related to the write-off of the initial note issuance costs for these 2015 Notes.
	In June 2014, we completed the exchange of $43.1 million in aggregate principal amount of 2017 Notes beneficially owned by certain existing holders of our 2017 Notes for an aggregate of 3,378,457 shares of our common stock (the “Exchange Shares”), valued at $47.22 per share, plus accrued but unpaid interest. The notes were exchanged at a rate of 78.3884 shares per $1,000 note, which represents an exchange price of approximately $12.77 per share and an approximate $0.10 discount from the original conversion price of the 2017 Notes of $12.87 per share. This exchange was accounted for as an extinguishment of notes and we recorded a loss on extinguishment of notes of $4.9 million which comprised $1.4 million of premium paid to the holders of the 2017 Notes, $2.9 million related to the excess of the deemed issuance fair value over the issuance price (par) of the Exchange Shares and $0.6 million related to the write-off of the initial note issuance costs for these notes.
	The following is a summary of the interest expense recognized on the 2017 Notes:
		Three Months				Six Months
		Ended June 30,				Ended June 30,
		2014		2013		2014		2013
		(in thousands)
	Contractual coupon interest expense	$	754	$	696	$	1,509	$	1,325
	Amortization of convertible note discount		1,566		1,348		3,095		2,484
	Amortization of convertible note issuance costs		193		199		385		329
	Total interest expense recognized on the 2017 Notes	$	2,513	$	2,243	$	4,989	$	4,138

Embedded_Conversion_Derivative

Embedded Conversion Derivative	6 Months Ended
	Jun. 30, 2014
Embedded Conversion Derivative	'
	10. EMBEDDED CONVERSION DERIVATIVE
	FASB Accounting Standards Codification (ASC) Topic 470 (ASC 470), Accounting for Convertible Debt Instruments That May be Settled in Cash upon Conversion (Including Partial Cash Settlement) requires the issuer of convertible debt that may be settled in shares or cash upon conversion at their option, such as our 2017 Notes, to account for their liability and equity components separately by bifurcating the embedded conversion derivative (the “derivative”) from the host debt instrument. Although ASC 470 has no impact on our actual past or future cash flows, it requires us to record non-cash interest expense as the debt discount is amortized.
	As a result of the issuance of convertible notes in January 2013, our total potential outstanding common stock exceeded our authorized shares by approximately 4.3 million shares as of that date, and we were therefore required to value the derivative and recognize the fair value as a long-term liability. The fair value of this derivative at the time of issuance was $36.9 million and was recorded as the original debt discount for the purposes of accounting for the debt component of the 2017 Notes. This debt discount is being amortized as interest expense using an effective interest rate of 9.9% over the remaining 3.5 year term of the 2017 Notes.
	In accordance with authoritative guidance, the embedded conversion derivative associated with the 2017 Notes required bifurcation from the 2017 Notes and was initially accounted for as a derivative liability. On May 30, 2013, upon obtaining stockholder approval for an amendment to our certificate of incorporation increasing the authorized number of shares of our common stock, the derivative liability was marked to fair value and reclassified to stockholders’ equity. Changes in the fair value were recorded in change in value of embedded conversion derivative in the condensed consolidated statements of operations. We determined the fair value of the derivative using a binomial lattice model. The key assumptions for determining the fair value at May 30, 2013 included the remaining time to maturity of 4.54 years, volatility of 50%, and the risk-free interest rate of 0.88%. The estimated fair value of the embedded conversion derivative was $34.5 million as of May 30, 2013 immediately prior to its reclassification to stockholders’ equity.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies	'
	11. COMMITMENTS AND CONTINGENCIES
	Details of our ongoing commitments and contingencies were described in Note 16 to our consolidated Financial Statements included in our 2013 Annual Report on Form 10-K for the fiscal year ended December 31, 2013. There have been no significant changes to these commitments and contingencies since December 31, 2013.
	Indemnity Agreement
	On or about March 22, 2000, we entered into an Indemnity Agreement with W. Scott Harkonen M.D., who served as the Company’s Chief Executive Officer until September 30, 2003. The Indemnity Agreement obligates us to hold harmless and indemnify Dr. Harkonen against expenses (including attorneys’ fees), witness fees, damages, judgments, fines and amounts paid in settlement and any other amounts Dr. Harkonen becomes legally obligated to pay because of any claim or claims made against him in connection with any threatened, pending or completed action, suit or proceeding, whether civil, criminal, arbitrational, administrative or investigative, to which Dr. Harkonen is a party by reason of the fact that he was a director, officer, employee or other agent of the Company. The Indemnity Agreement establishes exceptions to our indemnification obligation, including but not limited to claims “on account of Dr. Harkonen’s conduct that is established by a final judgment as knowingly fraudulent or deliberately dishonest or that constituted willful misconduct,” claims “on account of Dr. Harkonen’s conduct that is established by a final judgment as constituting a breach of Dr. Harkonen’s duty of loyalty to the Company or resulting in any personal profit or advantage to which Dr. Harkonen was not legally entitled,” and claims “for which payment is actually made to Dr. Harkonen under a valid and collectible insurance policy.” The Indemnity Agreement, however, obligates us to advance all expenses, including attorneys’ fees, incurred by Dr. Harkonen in connection with such proceedings, subject to an undertaking by Dr. Harkonen to repay said amounts if it shall be determined ultimately that he is not entitled to be indemnified by the Company.
	Dr. Harkonen was named as a defendant in certain civil action lawsuits instituted against us where the various complaints alleged that we fraudulently misrepresented the medical benefits of Actimmune for the treatment of IPF and promoted Actimmune for IPF. Ultimately, these complaints were dismissed. However, Dr. Harkonen also became the target of the investigation by the U.S. Department of Justice regarding the promotion and marketing of Actimmune. On March 18, 2008, a federal grand jury indicted Dr. Harkonen on two felony counts related to alleged improper promotion and marketing of Actimmune during the time Dr. Harkonen was employed by us (the “Criminal Action”). The trial in the criminal case resulted in a jury verdict on September 29, 2009, finding Dr. Harkonen guilty of one count of wire fraud related to a press release issued on August 28, 2002, and acquitting him of a second count of a misbranding charge brought under the Federal Food, Drug, and Cosmetic Act. On April 13, 2011, the Court denied Dr. Harkonen’s post-trial motions and sentenced Dr. Harkonen to three years of probation, including six months of home detention, 200 hours of community service and a fine of $20,000. The Court’s Judgment was filed on April 18, 2011. Dr. Harkonen appealed his conviction and sentence and the government cross-appealed his sentence. On March 4, 2013, the Ninth Circuit Court of Appeals issued an unpublished opinion affirming both the conviction and the sentence. Dr. Harkonen filed a petition for rehearing en banc which was denied by the Ninth Circuit Court of Appeals on May 7, 2013. On August 5, 2013, Dr. Harkonen filed a petition for a writ of certiorari seeking review by the United States Supreme Court. The U.S. Supreme Court denied Dr. Harkonen’s petition on December 16, 2013.
	Prior to December 2008, insurers that issued directors & officers (“D&O”) liability insurance to the Company had advanced all of Dr. Harkonen’s expenses, including attorneys’ fees, incurred in the civil action lawsuits and Criminal Action. Those insurers included National Union Fire Insurance Company of Pittsburgh, PA (“AIG”), Underwriters at Lloyd’s, London (“Lloyd’s”), and Continental Casualty Company (“CNA”). On November 19, 2008, however, the insurer that issued a $5.0 million D&O insurance policy providing coverage excess of the monetary limits of coverage provided by AIG, Lloyd’s and CNA, Arch Specialty Insurance Company (“Arch”), advised the Company that the limits of the underlying coverage were expected to be depleted by approximately December 15, 2008; that Arch “disclaimed coverage” based on misstatements and misrepresentations allegedly made by Dr. Harkonen in documents provided in the application for the Arch policy and the underlying Lloyd’s policy; and that, based on that disclaimer, Arch would not be advancing any of Dr. Harkonen’s expenses, including attorneys’ fees, incurred in the civil action lawsuits and Criminal Action.
	As a result of Arch’s disclaimer of coverage and refusal to advance expenses, including attorneys’ fees, the Company had, as of approximately December 15, 2008, become obligated to advance such expenses incurred by Dr. Harkonen in the civil action lawsuits and Criminal Action.
	On January 13, 2009, we submitted to the American Arbitration Association (“AAA”) a Demand for Arbitration, InterMune, Inc. v. Arch Specialty Insurance Co., No. 74 194 01128 08 JEMO. Dr. Harkonen also is a party to the Arbitration. The Demand for Arbitration sought an award compelling Arch to advance Dr. Harkonen’s legal fees and costs incurred in the civil action lawsuits and the Criminal Action, and to advance other former officers’ legal fees and costs incurred in relation to the Department of Justice investigation.
	The matter was heard by the arbitration panel and on May 29, 2009, the arbitration panel issued an Interim Arbitration Award granting our request for a partial award requiring Arch to advance Dr. Harkonen’s legal fees and costs incurred in the civil action lawsuits and Criminal Action. Arch subsequently advanced such fees and costs, including fees and costs previously paid by the Company. The question whether Arch ultimately will be required to cover the advanced fees and costs or, instead, may recoup those fees and costs as not covered by its policy, has not been determined. Unless and until the arbitration panel rules that such fees and costs are not covered, Arch remains obligated to advance such fees and costs.
	In late 2009, Arch advised us that Arch had exhausted the $5.0 million limit of liability of the Arch D&O insurance policy, and that defense cost invoices submitted to Arch collectively exceed the Arch policy’s limit. The Company therefore advised the insurer that issued a $5.0 million D&O insurance policy providing coverage for the excess of the monetary limits of coverage provided by Arch, Old Republic Insurance Company (“Old Republic”), that the limits of the underlying coverage had been depleted, and we submitted invoices for legal services rendered on behalf of Dr. Harkonen and other individuals who were targets of the U.S. Department of Justice’s investigation to Old Republic for payment. Old Republic agreed to advance Dr. Harkonen’s legal fees and costs incurred in the civil action lawsuits and Criminal Action, but declined to reimburse us for payments made on behalf of other individuals who were targets of the U.S. Department of Justice’s investigation. In mid-2010, Old Republic advised us that Dr. Harkonen’s defense fees and costs had exhausted the $5.0 million limit of the Old Republic insurance policy as of the second quarter of 2010. There is no additional insurance coverage available to cover the cost of Dr. Harkonen’s defense. Defense fees and costs incurred over and above this final $5.0 million of insurance coverage therefore are, in the absence of any available insurance, to be advanced by us and have been advanced by us pursuant to the terms of the Indemnity Agreement.
	Now that the United States Supreme Court has denied Dr. Harkonen’s petition for writ of certiorari, leaving the verdict and judgment against Dr. Harkonen intact, Arch has taken steps to resume the arbitration and seek to recoup all or some of the $5.0 million it advanced for Dr. Harkonen’s defense back from Dr. Harkonen and/or from the Company, contending that such fees and costs are not covered by its policy. In addition, Old Republic has written a letter dated May 8, 2014, claiming that Dr. Harkonen’s attorney’s fees and costs are not covered by its policy, and demanding that Dr. Harkonen and/or the Company repay the $5.0 million Old Republic advanced for Dr. Harkonen’s defense costs. The Company believes that Arch and Old Republic are not entitled to recover such fees and costs from the Company and will assert that position in arbitration. At this time, we believe no change to the status of the application of the D&O liability insurance in general has occurred due to the judgment in the Criminal Action. Therefore, while it is reasonably possible that we may incur a loss associated with this matter, we are unable to determine the amount of such a loss or range of losses and have not accrued for any such amounts in our financial statements associated with this matter.

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 30, 2014
Subsequent Events	'
	12. SUBSEQUENT EVENTS
	In July 2014, we completed the exchange of $41.0 million in aggregate principal amount of 2017 Notes beneficially owned by certain noteholders for (i) 3,185,703 shares of the our common stock (the “2017 Exchange Shares”), (ii) $1.3 million aggregate cash consideration and (iii) accrued but unpaid interest. For the share portion of the overall exchange consideration, the notes were exchanged at a rate of 77.7001 shares per $1,000 note, which represents an exchange price of approximately $12.87. This exchange price was the same as the original conversion price of the 2017 Notes. Additionally, in a separately negotiated private transaction with existing holders of 2017 Notes, we completed the exchange of $11.9 million in aggregate principal amount of 2017 Notes beneficially owned by the noteholders for (i) an aggregate of 908,423 2017 Exchange Shares, (ii) approximately $1.2 million aggregate cash consideration and (iii) accrued but unpaid interest. For the share portion of the overall exchange consideration, the notes were exchanged at a rate of 76.1461 shares per $1,000 note, which represents an exchange price of approximately $13.13 and an approximate $0.26 premium on the original conversion price of the 2017 Notes of $12.87 per share.
	In July 2014, we also completed the exchange of $16.9 million in aggregate principal amount of 2015 Notes beneficially owned by an existing noteholder for (i) an aggregate of 893,008 shares of our common stock (the “2015 Exchange Shares” and, together with the 2017 Exchange Shares, the “Exchange Shares”), (ii) $0.7 million aggregate cash consideration and (iii) accrued but unpaid interest. For the share portion of the overall exchange consideration, the notes were exchanged at a rate of 52.9661 shares per $1,000 note, which represents an exchange price of approximately $18.88 per share. This exchange price was the same as the original conversion price of the 2015 Notes.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. The financial statements include all adjustments (consisting only of normal recurring adjustments) that we believe are necessary for a fair presentation of the periods presented. The condensed consolidated balance sheet at December 31, 2013 was derived from the audited consolidated financial statements, but does not include all disclosures required by GAAP. These interim financial results are not necessarily indicative of results to be expected for the full fiscal year or any other future period and should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2013, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission, or SEC.
Revenue Recognition	'
	Revenue Recognition
	Revenue is generated from product sales and recorded net of mandatory government rebates. We only ship product upon receipt of valid orders from customers, such as pharmacies and hospitals, which are in turn a result of actual patient prescriptions. Delivery is considered to have occurred when title passes to a credit-worthy customer. We include shipping and handling costs in cost of goods sold. Pursuant to terms and conditions of sale, our customers have no general right of product return but we permit returns if the product is damaged or defective when received by the customer. Such restriction on product returns is common practice in the markets in which we sell, and as a result, we have had no significant expenses related to product returns, damaged or expired goods.
	To date, all significant amounts recorded as estimates of items that reduce gross revenue related solely to mandatory government rebates, many of which were negotiated on a confidential basis with the respective government reimbursement agencies. Our estimation of these rebates requires only the application of pre-specified rates, determined as part of pre-launch pricing negotiations with the relevant government reimbursement agencies, to sales of our product as applicable. We recognize these mandatory government rebates as reductions of product sales and the recording of these rebates is substantially mechanical in nature and does not involve the application of significant judgment. Fluctuations in the amounts recorded for these rebates relate solely to increased sales or the eventual payment of amounts due to the various government agencies. To date, we have had no significant charges or credits related to prior period estimates.
Derivative Financial Instruments	'
	Derivative Financial Instruments
	On January 22, 2013, we issued $120.8 million aggregate principal amount of 2.50% convertible senior notes due 2017 (the “2017 Notes”). As a result of our issuance of the 2017 Notes, our total potential outstanding common stock exceeded our authorized shares by approximately 4.3 million shares as of that date and we were therefore required to value the embedded conversion derivative and recognize it at fair value as a long-term liability.
	On May 30, 2013, we obtained stockholder approval to an amendment to our certificate of incorporation to increase the number of our authorized shares of common stock from 100,000,000 to 175,000,000. As a result of the increase in authorized number of shares, we can now settle the 2017 Notes in cash, stock, or a combination thereof, solely at our election, the derivative associated with the embedded conversion derivative was marked to fair value at May 30, 2013 and the long-term liability was reclassified to stockholders’ equity.
	See Note 10 for further details of our embedded conversion derivative.
Net Income (Loss) Per Share	'
	Net Income (Loss) Per Share
	Basic net loss per share is calculated based on the weighted-average number of shares of our common stock outstanding during the period, as adjusted. Diluted net loss per share is calculated based on the weighted average number of shares of our common and other dilutive securities outstanding during the period. The potential dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and shares subject to repurchase are determined under the treasury stock method. The potential dilutive shares of our common stock issuable on conversion of our convertible notes are determined using the “if-converted” method. Anti-dilutive securities, which consist of stock options, restricted stock awards and units, and shares that could be issued upon conversion of our convertible notes, are not included in the diluted net loss per share calculation.
	For the calculation of net loss per share, anti-dilutive securities excluded were as follows:
		As of
		June 30,
		2014			2013
		(in thousands)
	Common stock options and restricted awards and units		6,342			6,095
	Shares issuable upon conversion of convertible notes		11,888			15,237
	The following table is a reconciliation of the denominator used in the calculation of basic and diluted net loss per share attributable to our common stockholders:
		Three Months						Six Months
		Ended June 30,						Ended June 30,
		2014			2013			2014			2013
		(in thousands)
	Denominator:
	Weighted-average shares of common stock outstanding		99,631			81,823			95,360			79,924
	Less: Weighted-average shares subject to repurchase		(422	)		(613	)		(462	)		(603	)
	Weighted-average shares used in computing net income (loss) per common share – basic and diluted		99,209			81,210			94,898			79,321
Stock-Based Compensation	'
	Stock-Based Compensation
	The following table reflects stock-based compensation expense recognized for the three and six month periods ended June 30, 2014 and 2013:
		Three Months						Six Months
		Ended June 30,						Ended June 30,
		2014			2013			2014			2013
		(in thousands)
	Cost of goods sold	$	37		$	15		$	64		$	43
	Research and development		1,411			667			2,559			1,664
	Selling, general and administrative		3,757			2,023			6,865			3,786
	Total stock-based compensation expense	$	5,205		$	2,705		$	9,488		$	5,493
	Under the fair value recognition provisions of Accounting Standards Codification (ASC) 718-10, Stock Compensation, stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the vesting period for that portion of the award that is ultimately expected to vest. In order to estimate the value of share-based awards, we use the Black-Scholes model, which requires the use of certain subjective assumptions. The most significant assumptions are our estimates of the expected volatility, the expected term of the award and the estimated forfeiture rate.
Segment Reporting	'
	Segment Reporting
	We have determined, in accordance with ASC 280, Segment Reporting, that our business operates in one operating segment: the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In April 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-08, Presentation of Financial Statements and Property, Plant and Equipment. This ASU is an amendment to the discontinued operations accounting guidance. The amendment raises the threshold for a disposal to qualify as a discontinued operation and requires new disclosures for both discontinued operations and disposals of individually significant components that don’t qualify as discontinued operations. We adopted ASU No. 2014-08 for the period ended June 30, 2014. The adoption of this new guidance did not have an effect on our condensed consolidated balance sheets, statement of operations or cash flows.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2014
Schedule of Calculation of Net Loss Per Share, Anti-dilutive Securities Excluded	'
	For the calculation of net loss per share, anti-dilutive securities excluded were as follows:
		As of
		June 30,
		2014			2013
		(in thousands)
	Common stock options and restricted awards and units		6,342			6,095
	Shares issuable upon conversion of convertible notes		11,888			15,237
Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders	'
	The following table is a reconciliation of the denominator used in the calculation of basic and diluted net loss per share attributable to our common stockholders:
		Three Months						Six Months
		Ended June 30,						Ended June 30,
		2014			2013			2014			2013
		(in thousands)
	Denominator:
	Weighted-average shares of common stock outstanding		99,631			81,823			95,360			79,924
	Less: Weighted-average shares subject to repurchase		(422	)		(613	)		(462	)		(603	)
	Weighted-average shares used in computing net income (loss) per common share – basic and diluted		99,209			81,210			94,898			79,321
Stock-Based Compensation Expense Recognized	'
	The following table reflects stock-based compensation expense recognized for the three and six month periods ended June 30, 2014 and 2013:
		Three Months						Six Months
		Ended June 30,						Ended June 30,
		2014			2013			2014			2013
		(in thousands)
	Cost of goods sold	$	37		$	15		$	64		$	43
	Research and development		1,411			667			2,559			1,664
	Selling, general and administrative		3,757			2,023			6,865			3,786
	Total stock-based compensation expense	$	5,205		$	2,705		$	9,488		$	5,493

Discontinued_Operations_Tables

Discontinued Operations (Tables)	6 Months Ended
	Jun. 30, 2014
Summary Operating Results for Discontinued Operations	'
	Summary operating results for the discontinued operations are as follows:
		Three Months					Six Months
		Ended June 30,					Ended June 30,
		2014		2013			2014		2013
		(in thousands)
	Actimmune revenue, net	$	500	$	500		$	1,077	$	1,000
	Costs and expenses:
	General and administrative		15		(81	)		30		65
	Total costs and expenses		15		(81	)		30		65
	Income from discontinued operations		485		581			1,047		935
	Income and gains related to discontinued operations, before tax		485		581			1,047		935
	Income tax expense		165		194			356		318
	Income from discontinued operations, net of taxes	$	320	$	387		$	691	$	617

Fair_Value_Tables

Fair Value (Tables)	6 Months Ended
	Jun. 30, 2014
Financial Assets Measured at Fair Value on Recurring Basis	'
	The following table represents the fair value hierarchy for our financial assets which require fair value measurement on a recurring basis as of June 30, 2014 and December 31, 2013:
		As of June 30, 2014
		(in thousands)
	Assets	Level 1		Level 2			Level 3		Total
	Money market funds	$	52,364	$	—		$	—	$	52,364
	Obligations of government-sponsored enterprises		—		230,682			—		230,682
	Corporate debt securities		—		120,941			—		120,941
	Commercial paper		—		4,999			—		4,999
	Total	$	52,364	$	356,622		$	—	$	408,986
		As of December 31, 2013
		(in thousands)
	Assets	Level 1		Level 2			Level 3		Total
	Money market funds	$	40,739	$	—		$	—	$	40,739
	Obligations of government-sponsored enterprises		—		145,942			—		145,942
	Corporate debt securities		—		39,134			—		39,134
	Commercial paper		—		26,662			—		26,662
	Total	$	40,739	$	211,738		$	—	$	252,477
Summary of Carrying and Fair Value of Convertible Notes	'
	The following table summarizes the carrying and fair value of our Level 2 convertible senior notes as of June 30, 2014 and December 31, 2013:
		As of June 30, 2014					As of December 31, 2013
		(in thousands)
		Carrying value		Fair value			Carrying value		Fair value
	Convertible senior notes due 2015	$	18,360	$	43,026		$	18,360	$	21,028
	Convertible senior notes due 2017		60,868		267,380			91,492		166,563
	Convertible senior notes due 2018		155,250		232,566			155,250		139,930
	Total	$	234,478	$	542,972		$	265,102	$	327,521
Estimated Fair Value for Level 3 Classified Embedded Conversion Derivative	'
	The following table sets forth the changes in the estimated fair value for our Level 3 classified embedded conversion derivative:
		Three Months					Six Months
		Ended June 30,					Ended June 30,
		2014		2013			2014		2013
		(in thousands)
	Fair value measurement at beginning of period	$	—	$	28,129		$	—	$	—
	Embedded conversion derivative recorded in connection with 2017 Notes		—		—			—		36,887
	Change in fair value measurement included in operating expenses		—		6,336			—		(2,422	)
	Derivative liability reclassified to stockholders’ equity		—		(34,465	)		—		(34,465	)
	Fair value measurement at end of period	$	—	$	—		$	—	$	—

Cash_Equivalents_and_Available1

Cash Equivalents and Available-for-Sale Securities (Tables)	6 Months Ended
	Jun. 30, 2014
Summary of Available-for-Sale Debt and Equity Securities Included in Cash and Cash Equivalents or Available-for-Sale Securities	'
	The following table is a summary of available-for-sale debt and equity securities included in cash and cash equivalents or available-for-sale securities:
				Gross		Gross
		Amortized		unrealized		unrealized
		cost		gains		losses			Fair value
	30-Jun-14	(in thousands)
	Money market funds	$	52,364	$	—	$	—		$	52,364
	Obligations of government-sponsored enterprises		230,688		58		(64	)		230,682
	Corporate debt securities		120,980		16		(55	)		120,941
	Commercial paper		4,999		—		—			4,999
	Total	$	409,031	$	74	$	(119	)	$	408,986
		Amortized
		cost		Fair value
		(in thousands)
	Reported as:
	Cash equivalents	$	57,363	$	57,363
	Available-for-sale securities		351,668		351,623
	Total	$	409,031	$	408,986
				Gross		Gross
		Amortized		unrealized		unrealized
		cost		gains		losses			Fair value
	31-Dec-13	(in thousands)
	Money market funds	$	40,739	$	—	$	—		$	40,739
	Obligations of government-sponsored enterprises		145,890		52		—			145,942
	Corporate debt securities		39,123		18		(7	)		39,134
	Commercial paper		26,662		—		—			26,662
	Total	$	252,414	$	70	$	(7	)	$	252,477
		Amortized
		cost		Fair value
		(in thousands)
	Reported as:
	Cash equivalents	$	56,903	$	56,903
	Available-for-sale securities		195,511		195,574
	Total	$	252,414	$	252,477
Summary of Amortized Cost and Estimated Fair Value of Available-for-Sale Securities	'
	The following is a summary of the amortized cost and estimated fair value of available-for-sale securities by contractual maturity:
		30-Jun-14
		Amortized
		cost		Fair value
		(in thousands)
	Mature in less than one year	$	207,523	$	207,540
	Mature in one to three years		201,508		201,446
	Total	$	409,031	$	408,986

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Jun. 30, 2014
Schedule of Inventories	'
	Inventories consist of the following:
		June 30,		December 31,
		2014		2013
		(in thousands)
	Raw materials	$	5,653	$	6,962
	Work in process		3,317		1,951
	Finished goods		2,022		2,212
	Inventories	$	10,992	$	11,125

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	6 Months Ended
	Jun. 30, 2014
Schedule of Accumulated Other Comprehensive Income	'
	The components of accumulated other comprehensive income, net of taxes, were as follows:
							Accumulated
		Foreign		Unrealized gains			other
		currency		(losses) on			comprehensive
		translation		securities			income
		(in thousands)
	Balance at December 31, 2013	$	711	$	63		$	774
	Changes in components of other comprehensive income (loss)		88		(105	)		(17	)
	Balance at June 30, 2014	$	799	$	(42	)	$	757

Convertible_Notes_Tables

Convertible Notes (Tables) (Convertible Senior Notes Due 2017)	6 Months Ended
	Jun. 30, 2014
Convertible Senior Notes Due 2017	'
Summary of Interest Expense Recognized	'
	The following is a summary of the interest expense recognized on the 2017 Notes:
		Three Months				Six Months
		Ended June 30,				Ended June 30,
		2014		2013		2014		2013
		(in thousands)
	Contractual coupon interest expense	$	754	$	696	$	1,509	$	1,325
	Amortization of convertible note discount		1,566		1,348		3,095		2,484
	Amortization of convertible note issuance costs		193		199		385		329
	Total interest expense recognized on the 2017 Notes	$	2,513	$	2,243	$	4,989	$	4,138

Organization_Additional_Inform

Organization - Additional Information (Detail) (USD $)	6 Months Ended			1 Months Ended	6 Months Ended	1 Months Ended	6 Months Ended	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Jan. 31, 2013	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Jan. 31, 2013	Jun. 30, 2014
				Convertible Senior Notes Due 2017	Convertible Senior Notes Due 2017	Convertible Senior Notes Due 2017	Convertible Senior Notes Due 2017	Public Offerings	Public Offerings	European Union
						Certain Existing Holders	Certain Existing Holders			Country
Organization And Nature Of Operations [Line Items]	'	'	'	'	'	'	'	'	'	'
Number of member countries of the European Union ("EU") in which marketing authorization is granted	'	'	'	'	'	'	'	'	'	28
Common stock issued, shares	'	'	'	'	'	3,378,457	3,378,457	8,625,000	15,525,000	'
Proceeds from issuance of common stock in a public offering, net of issuance costs	$267,953	$145,734	'	'	'	'	'	$268,000	'	'
Debt Instrument Interest Rate Stated Percentage	2.50%	'	'	'	'	2.50%	2.50%	'	'	'
Convertible notes - noncurrent	$216,118	'	$265,102	'	$77,700	$43,100	$43,100	'	'	'
Shares issued, price per share	'	'	'	'	'	$47.22	$47.22	'	'	'
Debt instrument, convertible, conversion ratio	'	'	'	0.0777001	'	0.0783884	0.0783884	'	'	'
Convertible note conversion condition	'	'	'	'	'a) during any fiscal quarter beginning after June 30, 2013, if the last reported sale price of our common stock for at least 20 trading days during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price on each applicable trading day; b) during the five consecutive business day period after any five consecutive trading day period in which the trading price of the 2017 Notes falls below 98% of the product of (i) the last reported sale price of the Company’s common stock and (ii) the applicable conversion rate on each such trading date; c) if we call the 2017 Notes for redemption, at any time prior to the close of business on the second scheduled trading day prior to the redemption date; and d) upon the occurrence of specified corporate events, as defined in the 2017 Notes.	'	'The notes were exchanged at a rate of 78.3884 shares per $1,000 note	'	'	'
Debt instrument conversion price after discount	'	'	'	'	'	$12.77	$12.77	'	'	'
Debt instrument discount per share	'	'	'	'	'	$0.10	$0.10	'	'	'
Debt instrument original conversion price	'	'	'	$12.87	'	$12.87	$12.87	'	'	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	6 Months Ended			1 Months Ended
In Millions, except Share data, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Jan. 31, 2013	Jan. 22, 2013
				2.50% Convertible Senior Notes Due 2017	Senior Notes Issued
					2.50% Convertible Senior Notes Due 2017
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'
Total potential outstanding common stock in excess of authorized shares	'	'	'	4,300,000	'
Debt instrument, issued	'	'	'	'	$120.80
Convertible senior notes, maturity date	'Due 2017	'	'	'	'
Debt Instrument Interest Rate Stated Percentage	2.50%	'	'	'	'
Common stock, shares authorized	175,000,000	175,000,000	100,000,000	'	'

Schedule_of_Calculation_of_Net

Schedule of Calculation of Net Loss Per Share, Anti-dilutive Securities Excluded (Detail)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Common stock options and restricted awards and units	'	'
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]	'	'
Securities excluded from calculation of net loss per share	6,342	6,095
Shares issuable upon conversion of convertible notes	'	'
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]	'	'
Securities excluded from calculation of net loss per share	11,888	15,237

Reconciliation_of_Numerator_an

Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Detail)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]	'	'	'	'
Weighted-average shares of common stock outstanding	99,631	81,823	95,360	79,924
Less: Weighted-average shares subject to repurchase	-422	-613	-462	-603
Weighted-average shares used in computing net income (loss) per common share – basic and diluted	99,209	81,210	94,898	79,321

StockBased_Compensation_Expens

Stock-Based Compensation Expense Recognized (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'
Total stock-based compensation expense	$5,205	$2,705	$9,488	$5,493
Cost of goods sold	'	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'
Total stock-based compensation expense	37	15	64	43
Research and development	'	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'
Total stock-based compensation expense	1,411	667	2,559	1,664
Selling, general and administrative	'	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'
Total stock-based compensation expense	$3,757	$2,023	$6,865	$3,786

Discontinued_Operations_Additi

Discontinued Operations - Additional Information (Detail) (USD $)	1 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2012
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]	'
Proceeds from divestiture of Actimmune	$55
Conditional royalty payment period	'2 years

Summary_Operating_Results_for_

Summary Operating Results for Discontinued Operations (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]	'	'	'	'
Actimmune revenue, net	$500	$500	$1,077	$1,000
Costs and expenses:	'	'	'	'
General and administrative	15	-81	30	65
Total costs and expenses	15	-81	30	65
Income from discontinued operations	485	581	1,047	935
Income and gains related to discontinued operations, before tax	485	581	1,047	935
Income tax expense	165	194	356	318
Income from discontinued operations, net of taxes	$320	$387	$691	$617

Derivative_Instruments_Additio

Derivative Instruments - Additional Information (Detail)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2013
	USD ($)	USD ($)	USD ($)	USD ($)	CAD	EUR (€)	USD ($)	EUR (€)
Derivative [Line Items]	'	'	'	'	'	'	'	'
Derivative financial instruments not designated as hedges, net gain (loss)	($0.10)	($0.10)	($0.10)	$0.10	'	'	'	'
Notional value of outstanding currency hedges	'	'	'	'	5.5	17.7	'	9.5
Fair value of outstanding derivatives	$0	'	$0	'	'	'	$0.20	'

Financial_Assets_Measured_at_F

Financial Assets Measured at Fair Value on Recurring Basis (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	$408,986	$252,477
Obligations of government-sponsored enterprises	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	230,682	145,942
Corporate debt securities	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	120,941	39,134
Money Market Funds	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	52,364	40,739
Commercial Paper	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	4,999	26,662
Level 1	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	52,364	40,739
Level 1 | Money Market Funds	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	52,364	40,739
Level 2	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	356,622	211,738
Level 2 | Obligations of government-sponsored enterprises	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	230,682	145,942
Level 2 | Corporate debt securities	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	120,941	39,134
Level 2 | Commercial Paper	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	$4,999	$26,662

Fair_Value_Additional_Informat

Fair Value - Additional Information (Detail) (Level 2)	6 Months Ended
	Jun. 30, 2014
Level 2	'
Carrying Amounts And Fair Values Of Financial Instruments [Line Items]	'
Maximum Remaining Maturity of Foreign Currency Derivatives	'3 months

Summary_of_Carrying_and_Fair_V

Summary of Carrying and Fair Value of Convertible Notes (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Carrying Value Disclosure	'	'
Carrying Amounts And Fair Values Of Financial Instruments [Line Items]	'	'
Convertible senior notes	$234,478	$265,102
Fair Value	'	'
Carrying Amounts And Fair Values Of Financial Instruments [Line Items]	'	'
Convertible senior notes	542,972	327,521
Convertible Senior Notes Due 2015 | Carrying Value Disclosure	'	'
Carrying Amounts And Fair Values Of Financial Instruments [Line Items]	'	'
Convertible senior notes	18,360	18,360
Convertible Senior Notes Due 2015 | Fair Value	'	'
Carrying Amounts And Fair Values Of Financial Instruments [Line Items]	'	'
Convertible senior notes	43,026	21,028
Convertible Senior Notes Due 2017 | Carrying Value Disclosure	'	'
Carrying Amounts And Fair Values Of Financial Instruments [Line Items]	'	'
Convertible senior notes	60,868	91,492
Convertible Senior Notes Due 2017 | Fair Value	'	'
Carrying Amounts And Fair Values Of Financial Instruments [Line Items]	'	'
Convertible senior notes	267,380	166,563
Convertible Senior Notes Due 2018 | Carrying Value Disclosure	'	'
Carrying Amounts And Fair Values Of Financial Instruments [Line Items]	'	'
Convertible senior notes	155,250	155,250
Convertible Senior Notes Due 2018 | Fair Value	'	'
Carrying Amounts And Fair Values Of Financial Instruments [Line Items]	'	'
Convertible senior notes	$232,566	$139,930

Estimated_Fair_Value_for_Level

Estimated Fair Value for Level 3 Classified Embedded Conversion Derivative (Detail) (USD $)	3 Months Ended	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2014	30-May-13
Carrying Amounts And Fair Values Of Financial Instruments [Line Items]	'	'	'	'
Fair value measurement at beginning of period	'	$28,129	'	$34,500
Embedded conversion derivative recorded in connection with 2017 Notes	'	36,887	'	'
Change in fair value measurement included in operating expenses	6,336	-2,422	'	'
Derivative liability reclassified to stockholders’ equity	-34,465	-34,465	'	'
Fair value measurement at end of period	'	'	'	$34,500

Summary_of_AvailableforSale_De

Summary of Available-for-Sale Debt and Equity Securities Included in Cash and Cash Equivalents or Available-for-Sale Securities (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule Of Available For Sale Securities [Line Items]	'	'
Amortized cost	$409,031	$252,414
Gross unrealized gains	74	70
Gross unrealized losses	-119	-7
Available-for-sale securities	408,986	252,477
Cash Equivalents	'	'
Schedule Of Available For Sale Securities [Line Items]	'	'
Amortized cost	57,363	56,903
Available-for-sale securities	57,363	56,903
Available-for-sale Securities	'	'
Schedule Of Available For Sale Securities [Line Items]	'	'
Amortized cost	351,668	195,511
Available-for-sale securities	351,623	195,574
Obligations of government-sponsored enterprises	'	'
Schedule Of Available For Sale Securities [Line Items]	'	'
Amortized cost	230,688	145,890
Gross unrealized gains	58	52
Gross unrealized losses	-64	'
Available-for-sale securities	230,682	145,942
Corporate debt securities	'	'
Schedule Of Available For Sale Securities [Line Items]	'	'
Amortized cost	120,980	39,123
Gross unrealized gains	16	18
Gross unrealized losses	-55	-7
Available-for-sale securities	120,941	39,134
Money Market Funds	'	'
Schedule Of Available For Sale Securities [Line Items]	'	'
Amortized cost	52,364	40,739
Available-for-sale securities	52,364	40,739
Commercial Paper	'	'
Schedule Of Available For Sale Securities [Line Items]	'	'
Amortized cost	4,999	26,662
Available-for-sale securities	$4,999	$26,662

Cash_Equivalents_and_Available2

Cash Equivalents and Available-for-Sale Securities - Additional Information (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Cash And Cash Equivalents [Line Items]	'	'
Cash	$151.20	$134.50

Summary_of_Amortized_Cost_and_

Summary of Amortized Cost and Estimated Fair Value of Available-for-Sale Securities (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule Of Available For Sale Securities [Line Items]	'	'
Available-for-sale securities, Mature in less than one year, Amortized Cost	$207,523	'
Available-for-sale securities, Mature in one to three years, Amortized Cost	201,508	'
Available-for-sale securities, Amortized Cost, Total	409,031	252,414
Available-for-sale securities, Mature in less than one year, Fair Value	207,540	'
Available-for-sale securities, Mature in one to three years, Fair Value	201,446	'
Available-for-sale securities, Fair Value, Total	$408,986	$252,477

Schedule_of_Inventories_Detail

Schedule of Inventories (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory [Line Items]	'	'
Raw materials	$5,653	$6,962
Work in process	3,317	1,951
Finished goods	2,022	2,212
Inventories	$10,992	$11,125

Schedule_of_Accumulated_Other_

Schedule of Accumulated Other Comprehensive Income (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Accumulated Other Comprehensive Income Loss [Line Items]	'	'	'	'
Beginning Balance	'	'	$711	'
Changes in components of other comprehensive income (loss)	144	-109	88	-664
Ending Balance	799	'	799	'
Beginning Balance	'	'	63	'
Changes in components of other comprehensive income (loss)	'	'	-105	'
Ending Balance	-42	'	-42	'
Beginning Balance	'	'	774	'
Changes in components of other comprehensive income (loss)	47	-197	-17	-797
Ending Balance	$757	'	$757	'

Convertible_Notes_Additional_I

Convertible Notes - Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Mar. 31, 2014

Jan. 31, 2013

Jan. 31, 2013

Jan. 31, 2013

Jun. 30, 2008

Jun. 30, 2014

Jan. 31, 2013

Sep. 30, 2011

Jun. 30, 2014

Jun. 30, 2014

Jan. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jan. 31, 2013

Public Offerings

Public Offerings

Public Offerings

Convertible Senior Notes Due 2015

Convertible Senior Notes Due 2015

Convertible Senior Notes Due 2015

Convertible Senior Notes Due 2015

Convertible Senior Notes Due 2018

Convertible Senior Notes Due 2018

Convertible Senior Notes Due 2017

Convertible Senior Notes Due 2017

Convertible Senior Notes Due 2017

Convertible Senior Notes Due 2017

Convertible Senior Notes Due 2017

Convertible Senior Notes Due 2017

Convertible Senior Notes Due 2017

Convertible Senior Notes Due 2017

Common Stock Offering

Repurchase

Certain Existing Holders

Certain Existing Holders

Minimum

Maximum

Senior Notes Issued

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument amount outstanding

$216,118,000

$216,118,000

'

$265,102,000

'

'

'

'

$85,000,000

$18,400,000

'

$155,300,000

$155,300,000

$77,700,000

'

$77,700,000

$43,100,000

$43,100,000

'

'

'

Debt Instrument Interest Rate Stated Percentage

2.50%

2.50%

'

'

'

'

'

'

5.00%

'

'

2.50%

'

'

'

'

2.50%

2.50%

'

'

2.50%

Debt instrument maturity date

'

'

'

'

'

'

'

'

1-Mar-15

'

'

15-Sep-18

'

'

'

15-Dec-17

'

'

'

'

'

Debt instrument, convertible, conversion ratio

'

'

'

'

'

'

'

'

0.0529661

'

'

0.0314465

'

'

0.0777001

'

0.0783884

0.0783884

'

'

'

Debt instrument original conversion price

'

'

'

'

'

'

'

'

$18.88

'

'

$31.80

'

'

$12.87

'

$12.87

$12.87

'

'

'

Offering expenses and underwriting discounts

'

'

'

'

'

'

'

'

600,000

'

'

5,000,000

'

'

'

'

'

'

'

'

'

Period from inception in which offering costs are amortized, years

'

'

'

'

'

'

'

'

'7 years

'

'

'7 years

'

'

'

'

'

'

'

'

'

Common stock issued, shares

'

'

'

'

8,625,000

15,525,000

'

'

'

'

'

'

'

'

'

'

3,378,457

3,378,457

'

'

'

Debt instrument, issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

120,800,000

Aggregate net proceeds from common stock offerings

'

267,953,000

145,734,000

'

268,000,000

'

145,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate net proceeds from convertible note offering

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

116,800,000

Convertible senior notes, maturity date

'

'Due 2017

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Due December 15, 2017

Convertible note conversion condition

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'a) during any fiscal quarter beginning after June 30, 2013, if the last reported sale price of our common stock for at least 20 trading days during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price on each applicable trading day; b) during the five consecutive business day period after any five consecutive trading day period in which the trading price of the 2017 Notes falls below 98% of the product of (i) the last reported sale price of the Company’s common stock and (ii) the applicable conversion rate on each such trading date; c) if we call the 2017 Notes for redemption, at any time prior to the close of business on the second scheduled trading day prior to the redemption date; and d) upon the occurrence of specified corporate events, as defined in the 2017 Notes.

'

'The notes were exchanged at a rate of 78.3884 shares per $1,000 note

'

'

'

Number of consecutive trading days used in conversion analysis

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'30 days

'

'

'20 days

'

'

Market price of common stock exceeding percent of the conversion price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

130.00%

'

'

'

'

'

Number of consecutive business days for the market price of notes to fall below the 98% threshold

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 days

'

'

'

'

'

Number of consecutive trading days for the market price of notes to fall below the 98% threshold

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 days

'

'

'

'

'

Market price of notes declining to percent of the value of the common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

98.00%

'

Redemption price percentage of the notes to be redeemed

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

Debt instrument repurchased amount

'

'

'

'

'

'

'

'

'

'

66,600,000

'

'

'

'

'

'

'

'

'

'

Repurchase of convertible senior notes

'

'

'

'

'

'

'

72,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss on extinguishment of notes

4,934,000

4,934,000

7,900,000

'

'

'

'

7,900,000

'

'

'

'

'

4,900,000

'

'

'

'

'

'

'

Premium paid to the holders

'

'

'

'

'

'

'

5,500,000

'

'

'

'

'

1,400,000

'

'

'

'

'

'

'

Excess of deemed issuance fair value over issuance price

'

'

'

'

'

'

'

2,200,000

'

'

'

'

'

2,900,000

'

'

'

'

'

'

'

Write-off of the initial debt issuance costs

'

'

'

'

'

'

'

200,000

'

'

'

'

'

600,000

'

'

'

'

'

'

'

Convertible notes - noncurrent

$216,118,000

$216,118,000

'

$265,102,000

'

'

'

'

$85,000,000

$18,400,000

'

$155,300,000

$155,300,000

$77,700,000

'

$77,700,000

$43,100,000

$43,100,000

'

'

'

Shares issued, price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$47.22

$47.22

'

'

'

Debt instrument conversion price after discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$12.77

$12.77

'

'

'

Debt instrument discount per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.10

$0.10

'

'

'

Summary_of_Interest_Expense_Re

Summary of Interest Expense Recognized (Detail) (Convertible Senior Notes Due 2017, USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Convertible Senior Notes Due 2017	'	'	'	'
Interest Expense [Line Items]	'	'	'	'
Contractual coupon interest expense	$754	$696	$1,509	$1,325
Amortization of convertible note discount	1,566	1,348	3,095	2,484
Amortization of convertible note issuance costs	193	199	385	329
Total interest expense recognized on the 2017 Notes	$2,513	$2,243	$4,989	$4,138

Embedded_Conversion_Derivative1

Embedded Conversion Derivative - Additional Information (Detail) (USD $)	0 Months Ended	6 Months Ended			1 Months Ended	6 Months Ended
In Thousands, except Share data in Millions, unless otherwise specified	30-May-13	Jun. 30, 2013	Jun. 30, 2014	Dec. 31, 2012	Jan. 31, 2013	Jun. 30, 2014
					2.50% Convertible Senior Notes Due 2017	2.50% Convertible Senior Notes Due 2017
Derivative [Line Items]	'	'	'	'	'	'
Total potential outstanding common stock in excess of authorized shares	'	'	'	'	4.3	'
Embedded conversion derivative recorded in connection with 2017 Notes	'	$36,887	'	'	$36,900	'
Effective interest rate	'	'	'	'	'	9.90%
Debt discount amortization period	'	'	'	'	'	'3 years 6 months
Fair value assumptions, maturity period	'4 years 6 months 15 days	'	'	'	'	'
Fair value assumptions, volatility rates	50.00%	'	'	'	'	'
Fair value assumptions, risk free interest rate	0.88%	'	'	'	'	'
Fair value assumptions, embedded conversion derivative	$34,500	'	'	$28,129	'	'

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	0 Months Ended
	Apr. 13, 2011	18-May-08	Nov. 19, 2008	8-May-14
		Claim	Directors And Officers Insurance Policy	Old Republic
Loss Contingencies [Line Items]	'	'	'	'
Number of felony counts indicted on Dr. Harkonen	'	2	'	'
Litigation Settlement Fine Levied Against Third Party Defendant	$20,000	'	'	'
Carrying amount of insurance policy	'	'	5,000,000	'
Repayment of costs not covered by policy	'	'	'	$5,000,000

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)

Jun. 30, 2014

Dec. 31, 2013

Jan. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jan. 31, 2013

Jun. 30, 2008

Jun. 30, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Convertible Senior Notes Due 2017

Convertible Senior Notes Due 2017

Convertible Senior Notes Due 2017

Convertible Senior Notes Due 2017

Convertible Senior Notes Due 2015

Convertible Senior Notes Due 2015

Convertible Senior Notes Due 2015

Subsequent Event

Subsequent Event

Subsequent Event

Certain Existing Holders

Certain Existing Holders

Convertible Senior Notes Due 2017

Convertible Senior Notes Due 2017

Convertible Senior Notes Due 2015

Certain Existing Holders

Private Transaction With Existing Holders

Negotiated Private Transaction Of Notes

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Convertible notes - noncurrent

$216,118,000

$265,102,000

'

$77,700,000

$43,100,000

$43,100,000

'

$85,000,000

$18,400,000

$41,000,000

$11,900,000

$16,900,000

Common stock issued, shares

'

'

'

'

3,378,457

3,378,457

'

'

'

3,185,703

908,423

893,008

Repurchase of convertible senior notes

'

'

'

'

'

'

$72,200,000

'

'

$1,300,000

$1,200,000

$700,000

Debt instrument original conversion price

'

'

$12.87

'

$12.87

$12.87

'

$18.88

'

$12.87

$13.13

$18.88

Debt instrument, convertible, conversion ratio

'

'

0.0777001

'

0.0783884

0.0783884

'

0.0529661

'

0.0777001

0.0761461

0.0529661

Debt instrument premium

'

'

'

'

'

'

'

'

'

'

$0.26

'